APRINOIA Therapeutics announces today that the U.S. Food and Drug 
Administration (FDA) has granted a may proceed authorization for its novel 
therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to 
test and evaluate its safety in healthy subjects in a phase 1 single ascending 
dose study.

APNmAb005 is a unique antibody that recognizes a conformation-dependent epitope 
present only in pathological forms of tau proteins. It preferentially targets a 
population of misfolded tau proteins segregated in specific cellular 
compartments, including synapses in brains of patients with Alzheimer's 
Disease(AD), as well as primary tauopathies, such as Progressive Supranuclear 
Palsy (PSP) and other forms of Frontotemporal Lobar Degeneration (FTLD). 

"This is an exciting and important milestone in the history of APRINOIA, which 
aims to develop novel therapeutics that target misfolded proteins implicated in 
neurodegenerative disorders in addition to developing brain imaging agents that 
will enable detection of these proteins. Therapeutic agents targeting tau 
proteins have emerged as an important strategy to tackle those diseases. The 
pathological tau population identified by APNmAb005 provides new insight into 
tau pathology and new possibilities for the discovery of more precise and 
targeted treatments", said Dr. Bradford A. Navia, Chief Medical Officer of 
APRINOIA.

About APNmAb005 

APNmAb005 is a humanized anti-tau antibody specifically targeting human tau 
aggregates found in tau-related diseases including Alzheimer's Disease, 
Progressive Supranuclear Palsy, Corticobasal Degeneration, and other forms of 
Frontotemporal Lobar Degeneration. APNmAb005 preferentially binds tau 
aggregates accumulated at the neuronal synapses of AD patients, specialized 
sites critical for information transfer and release of transmissible abnormal 
tau species between brain cells. Clearance of tau aggregates at neuronal 
synapses by APNmAb005 is expected to significantly reduce tau pathology, 
synaptic injury, thereby slowing disease progression and restoring brain and 
cognitive health.

About APRINOIA Therapeutics

APRINOIA is a late-stage biotechnology company committed to protecting 
patients' brain health and changing outcomes of neurodegenerative diseases 
through first-in-class and best-in-class diagnostic tools and novel therapies. 
The company aims to bring precision medicine to neuroscience by identifying and 
targeting the protein aggregates of tau, alpha-synuclein and other proteins 
that play a critical role in the pathogenesis of many neurodegenerative 
diseases, such as Alzheimer's and Parkinson's Diseases. The company currently 
has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.

SOURCE: APRINOIA Therapeutics